The Hypothesis

I suspect the breakdown of retrograde transport in aging Basal Forebrain Cholinergic Neurons (BFCNs) isn't just about nitrative stress or physical blockages. Instead, it’s a downstream consequence of impaired axonal mitophagy. When this process fails, "aged" signaling endosomes and dysfunctional mitochondria pile up in the distal axon, creating a bottleneck. My hypothesis is that by selectively boosting mitophagy—specifically through PINK1/Parkin activation in the axon—we can clear this debris and restore the fluid transport dynamics needed for TrkA-NGF and TrkB-BDNF signaling. This would effectively reverse atrophy without ever needing exogenous neurotrophins.

Mechanistic Rationale

We know that proNGF accumulation triggers p75NTR-mediated degeneration, likely through JNK-induced axonal toxicity (Science Signaling). But even when we look at mature NGF/TrkA complexes, their transit is hampered by axonal defects that go beyond simple nitrative damage (PubMed). I propose these "defects" are really metabolic bottlenecks: as BFCNs age, the axonal mitochondrial pool gets carbonylated and fragmented. Once these mitochondria lose their membrane potential, they can’t provide the energy dynein needs to haul neurotrophic endosomes back to the soma.

It’s likely that age-related nitrative stress inhibits the mitophagy machinery itself—perhaps through S-nitrosylation of Parkin (Frontiers in Molecular Neuroscience). In the ultra-long axons of BFCNs, inhibited mitophagy means the cytoplasm gets crowded with damaged organelles, physically obstructing molecular motors like dynein/dynactin complexes. This explains why these neurons stay alive but stay "phenotypically silent"—the receptor-ligand complexes are sitting at the synapse, but the "railway" is buried in metabolic waste.

Testable Predictions

1. Colocalization Analysis: In human-induced BFCNs (hiBFCNs) ([PMC7579825]), retrograde endosomes (TrkA+) should show significantly more colocalization with damaged, depolarized mitochondria (indicated by MitoTracker/TMRE loss) than we see in young controls.
2. Mitophagy Induction: Pharmacologically activating the PINK1/Parkin pathway—using small-molecule mitochondrial stabilizers—in aged hiBFCNs should restore the kinetics of NGF retrograde transport, which we can track via live-cell imaging of fluorescently labeled NGF/TrkA endosomes.
3. Reversal of Atrophy: Enhancing axonal mitophagy ought to increase ChAT expression and BFCN soma size, achieving the same results as exogenous NGF infusion by simply tapping into the neuron’s own endogenous supply.

Perspective

If transport failure is primarily a result of metabolic clutter, then forcing neurotrophins into the system is just a temporary bandage that ignores the actual axonal degradation. By resetting the mitophagy threshold, we shift from "bypass" to "restorative" therapy. This might even prevent the TAU hyperphosphorylation and nucleocytoplasmic transport issues we see in AD-linked hiBFCN models ([PMC7579825]). This model offers an actionable target for drug screening that moves us past merely observing BFCN loss and toward actively fixing axonal homeostasis.